BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
The Best Games Crossroads in History - 2Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- 3Germany expresses 'great concern' over Israel's new death penalty law
- 4JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- 5Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- Favored Chinese Dish: Make Your Determination
- Building a Flourishing Business: Illustrations from Business people
- CVS forecasts 2026 profit above estimates on strong performance
- Investigating Cooking and Culinary Expressions: An Excursion Through Flavors
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- Hoist Your Style: Famous Hairdos for Ladies
- Birutė Galdikas: The last of the ‘angels’ in primatology’s most extraordinary chapter
- Disability rights activist and author Alice Wong dies at 51
